Blockade of IL10 signaling promotes TLR9-driven liver dysfunction by allowing T cell receptor-mediated T cell activation

Objective Deficient IL10 signaling can contribute to macrophage activation syndrome (MAS). TLR-9 drives innate immune activation and has been used to model MAS. IL10 promotes T cell tolerance and the development of T regulatory cells. We hypothesized that in TLR-9-mediated innate immune activation, blocking IL10 would increase T cell activation and worsen MAS-associated organ dysfunction. Methods C57BL/6 mice (n=3-11/cohort) were injected with A) CpG ODN1826, a TLR9 agonist, 50μg every other day for 5 doses on days -8 — 0 (CpGLo), B) CpG 500μg on Day 0 (CpGHi), or C) CpGHi+αIL10-R blocking antibody. OTI and OTII mice, which respectively contain CD8 and CD4 cells with transgenic T cell receptors, do not respond to antigens. Wild-type C57Bl/6, OTI, and OTII mice received CpGHi+αIL10-R. Baseline (untreated) mice were included in each experiment. Animals were sacrificed one day post-challenge. Results The CpGHi cohort had lower WBC ( p< 0.0001), higher ferritin ( p = 0.0035) and higher ALT ( p< 0.05) and lower bile acid transporter mRNA levels ( p < 0.05). The CpGHi cohort had increased percentages of B cells expressing activation markers (CD80, CD86, and MHC-I, p< 0.05), of dendritic cells expressing CD86 ( p= 0.03), and of CD4 ( p< 0.0001) and CD8 ( p= 0.025) T cells expressing CD69. Compared to CpGHi, CpGHi+αIL10-R treatment increased Nur77 expression on CD4 and CD8 T cells ( p< 0.0001), did not alter innate immune cells, and was associated with worse liver function ( p< 0.05). We noted significant expansion of Nur77 + CD69 + CD8 T cells in OTI and OTII mice, indicating a TCR-associated activation leading to a CD8 T cell response. Conclusions In TLR9-induced hyperinflammation, IL10 restrained a feedforward loop of innate and T cell activation. The specificity of the innate and T cell interaction is unclear and may represent an autoimmune activation of CD8 T cells.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1941873
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Blockade of IL10 signaling promotes TLR9-driven liver dysfunction by allowing T cell receptor-mediated T cell activation

Shivani Chhabra, Mariana R. Brewer, Matthew Eremita, Grace M. Fisler et al.
2 links
Frontiers in Immunology
Autoimmune and Inflammatory Disorders Research
article

Blockade of IL10 signaling promotes TLR9-driven liver dysfunction by allowing T cell receptor-mediated T cell activation

Shivani Chhabra, Mariana R. Brewer, Matthew Eremita, Grace M. Fisler, Joyce S Hui‐Yuen, Clifford Scott Deutschman, Mei Qi, Matthew D. Taylor
article en

Abstract

Objective Deficient IL10 signaling can contribute to macrophage activation syndrome (MAS). TLR-9 drives innate immune activation and has been used to model MAS. IL10 promotes T cell tolerance and the development of T regulatory cells. We hypothesized that in TLR-9-mediated innate immune activation, blocking IL10 would increase T cell activation and worsen MAS-associated organ dysfunction. Methods C57BL/6 mice (n=3-11/cohort) were injected with A) CpG ODN1826, a TLR9 agonist, 50μg every other day for 5 doses on days -8 — 0 (CpGLo), B) CpG 500μg on Day 0 (CpGHi), or C) CpGHi+αIL10-R blocking antibody. OTI and OTII mice, which respectively contain CD8 and CD4 cells with transgenic T cell receptors, do not respond to antigens. Wild-type C57Bl/6, OTI, and OTII mice received CpGHi+αIL10-R. Baseline (untreated) mice were included in each experiment. Animals were sacrificed one day post-challenge. Results The CpGHi cohort had lower WBC ( p< 0.0001), higher ferritin ( p = 0.0035) and higher ALT ( p< 0.05) and lower bile acid transporter mRNA levels ( p < 0.05). The CpGHi cohort had increased percentages of B cells expressing activation markers (CD80, CD86, and MHC-I, p< 0.05), of dendritic cells expressing CD86 ( p= 0.03), and of CD4 ( p< 0.0001) and CD8 ( p= 0.025) T cells expressing CD69. Compared to CpGHi, CpGHi+αIL10-R treatment increased Nur77 expression on CD4 and CD8 T cells ( p< 0.0001), did not alter innate immune cells, and was associated with worse liver function ( p< 0.05). We noted significant expansion of Nur77 + CD69 + CD8 T cells in OTI and OTII mice, indicating a TCR-associated activation leading to a CD8 T cell response. Conclusions In TLR9-induced hyperinflammation, IL10 restrained a feedforward loop of innate and T cell activation. The specificity of the innate and T cell interaction is unclear and may represent an autoimmune activation of CD8 T cells.

Frontiers in ImmunologyVol. 17
Northwell Health (US), Feinstein Institute for Medical Research (US), North Shore Diabetes and Endocrine Associates (US)
Rheumatology Research Foundation, Childhood Arthritis and Rheumatology Research Alliance, National Institutes of Health, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Good health and well-being
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon